Background: Lanreotide-Autogel is a depot formulation of the somatostatin analog lanreotide used in the treatment of acromegaly. We investigated whether prolonging or shortening the interval between injections would offer any benefit. Subjects and methods: The interval was prolonged from once every 4 weeks to once every 6 weeks when patients (n = 9) had normal IGF-I and GH concentrations. When patients (n = 12) had still elevated IGF-I or GH on the maximal dose of 1.20 mg every 4 weeks, the interval was shortened to once every 3 weeks. Serum IGF-I and GH were measured after 12 and 24 weeks to allow for dose adaptation. Symptoms and tumor volume were evaluated at baseline and after 36 weeks. Results: In seven of the nine subjects with normal IGF-I and GH, the interval could be extended to 6 weeks without loosing efficacy on IGF-I (195 vs 213 mu g/l; not significant, NS) and GH concentrations (1.4 vs 1.3 mu g/l; NS). The weekly dose could significantly be reduced (from 23.3 to 17.8 mg; P=0.002). In only 1 of the 12 not-controlled patients, reducing the interval to once every 3 weeks induced normalization of IGF-I and GH. Conclusion: In subjects whose acromegaly is well controlled using lanreotide-Autogel, prolonging the time interval between injections can often be increased 4 to 6 weeks without loss of efficacy, thereby improving the subject's comfort and reducing the cost of treatment. On the other hand, in subjects whose acromegaly is not controlled on a dose of 120 mg every 4 weeks, reducing the interval to every 3 weeks is rarely beneficial.
Abrams, P., Alexopoulou, O., Abs, R., Maiter, D., & Verhelst, J. (2007). Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. European Journal of Endocrinology, 157(5), 571-577. https://doi.org/10.1530/EJE-07-0366 (Original work published 2007)